From DCAT Value Chain Insights (VCI)
Incyte Corporation, a biopharmaceutical company focused on small-molecule oncology drugs, has appointed David Gryska as executive vice president and chief financial officer (CFO), effective October 31, 2014. He will report to Hervé Hoppenot, president and chief executive officer.
Mr. Gryska will succeed David Hastings, who has served as Incyte’s executive vice president and CFO since October 2003. Mr. Hastings, who is leaving the company to pursue other opportunities, will remain with Incyte through the end of November and will work closely with Mr. Gryska to ensure a seamless transition.
Mr. Gryska brings over 30 years of finance experience to Incyte from his tenures at Celgene and Scios and through his work with a number of publicly traded biotech companies. He is a three-time public company CFO with proven skills across multiple finance disciplines.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription